These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 16413656)
1. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Kalsi V; Popat RB; Apostolidis A; Kavia R; Odeyemi IA; Dakin HA; Warner J; Elneil S; Fowler CJ; Dasgupta P Eur Urol; 2006 Mar; 49(3):519-27. PubMed ID: 16413656 [TBL] [Abstract][Full Text] [Related]
2. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. Popat R; Apostolidis A; Kalsi V; Gonzales G; Fowler CJ; Dasgupta P J Urol; 2005 Sep; 174(3):984-9. PubMed ID: 16094019 [TBL] [Abstract][Full Text] [Related]
3. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Kalsi V; Apostolidis A; Popat R; Gonzales G; Fowler CJ; Dasgupta P Eur Urol; 2006 Mar; 49(3):528-35. PubMed ID: 16426735 [TBL] [Abstract][Full Text] [Related]
4. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment. Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216 [TBL] [Abstract][Full Text] [Related]
5. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127 [TBL] [Abstract][Full Text] [Related]
6. Injections of Botulinum Toxin A into the detrusor to treat neurogenic detrusor overactivity secondary to spinal cord injury. Chen G; Liao L Int Urol Nephrol; 2011 Sep; 43(3):655-62. PubMed ID: 21110094 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity. Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367 [TBL] [Abstract][Full Text] [Related]
8. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. Apostolidis A; Popat R; Yiangou Y; Cockayne D; Ford AP; Davis JB; Dasgupta P; Fowler CJ; Anand P J Urol; 2005 Sep; 174(3):977-82; discussion 982-3. PubMed ID: 16094018 [TBL] [Abstract][Full Text] [Related]
9. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Grosse J; Kramer G; Stöhrer M Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758 [TBL] [Abstract][Full Text] [Related]
11. How to assess and predict success or failure of intra-detrusor injections with onabotulinumtoxinA. Przydacz M; Golabek T; Chlosta P Adv Clin Exp Med; 2019 Apr; 28(4):555-567. PubMed ID: 30729759 [TBL] [Abstract][Full Text] [Related]
12. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Kuo HC Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967 [TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity. Alvares RA; Silva JA; Barboza AL; Monteiro RT Int Braz J Urol; 2010; 36(6):732-7. PubMed ID: 21176280 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective. Hamid R; Loveman C; Millen J; Globe D; Corbell C; Colayco D; Stanisic S; Gultyaev D Pharmacoeconomics; 2015 Apr; 33(4):381-93. PubMed ID: 25526842 [TBL] [Abstract][Full Text] [Related]
16. Switch to Abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of Onabotulinum toxin A failed. Bottet F; Peyronnet B; Boissier R; Reiss B; Previnaire JG; Manunta A; Kerdraon J; Ruffion A; Lenormand L; Perrouin Verbe B; Gaillet S; Gamé X; Karsenty G; Neurourol Urodyn; 2018 Jan; 37(1):291-297. PubMed ID: 28431196 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658 [TBL] [Abstract][Full Text] [Related]
18. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Kessler TM; Danuser H; Schumacher M; Studer UE; Burkhard FC Neurourol Urodyn; 2005; 24(3):231-6. PubMed ID: 15747344 [TBL] [Abstract][Full Text] [Related]
19. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity. Kanagarajah P; Ayyathurai R; Caruso DJ; Gomez C; Gousse AE Int Urol Nephrol; 2012 Feb; 44(1):91-7. PubMed ID: 21643644 [TBL] [Abstract][Full Text] [Related]
20. Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders. Lin YH; Chiang BJ; Liao CH Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]